Skip to main content
Shubham Pant, MD, Oncology, Oklahoma City, OK

ShubhamPantMD

Oncology Oklahoma City, OK

Associate Professor of Medicine & Director of Clinical Trials, Hematology/Oncology Section of the Stephenson Cancer Center in Oklahoma City.

Dr. Pant is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Pant's full profile

Already have an account?

  • Office

    1515 Holcombe Blvd
    Oklahoma City, OK 77030
    Phone+1 405-271-8299

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008
  • University of Oklahoma Health Sciences Center
    University of Oklahoma Health Sciences CenterResidency, Internal Medicine, 2002 - 2005
  • Maulana Azad Medical College
    Maulana Azad Medical CollegeClass of 2001

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • AZ State Medical License
    AZ State Medical License 2023 - 2026
  • GA State Medical License
    GA State Medical License 2023 - 2026
  • TN State Medical License
    TN State Medical License 2023 - 2026
  • TX State Medical License
    TX State Medical License 2015 - 2026
  • LA State Medical License
    LA State Medical License 2023 - 2025
  • MS State Medical License
    MS State Medical License 2023 - 2025
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma  
    Shubham Pant, Milind Javle, Naruhiko Ikoma, Ching-Wei Tzeng, Jeffrey E Lee, JAMA Surgery

Lectures

  • Tyme-88-Panc Part 2: A randomized phase II/III of SM-88 with MPS as third-line in metastatic PDAC. 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
  • A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts). 
    2019 ASCO Annual Meeting - 6/1/2019
  • A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Join now to see all

Other

Authored Content

  • Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020
  • Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020

Press Mentions

  • Exploring Pancreatic Cancer Vaccines: What’s Next?
    Exploring Pancreatic Cancer Vaccines: What’s Next?November 21st, 2024
  • MD Anderson Research Highlights: ASCO 2023 Special Edition
    MD Anderson Research Highlights: ASCO 2023 Special EditionMay 25th, 2023
  • Don't Ignore These Pancreatic Cancer Warning Signs
    Don't Ignore These Pancreatic Cancer Warning SignsApril 28th, 2023
  • Join now to see all

Professional Memberships